ClinicalTrials.gg
Active, not recruitingNCT03344848Updated Jan 27, 2025

Early Feasibility Study of the Orion Visual Cortical Prosthesis System

An interventional study of Orion Visual Cortical Prosthesis System in Blindness, Acquired, sponsored by Second Sight Medical Products. Active, not recruiting at 2 sites in United States. Open to participants aged 22 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Second Sight Medical Products · Not applicable, Interventional, and Device feasibility

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
22 Years to 74 Years
Sex
All
01

Study summary

This is an early feasibility study of a new device, the Orion Visual Cortical Prosthesis System. The device is intended to stimulate the surface of the visual cortex to induce visual perception in blind individuals.

Read the detailed description

In this study, 6 subjects with bare light or no light perception in both eyes will be implanted with the Orion Cortical Visual Prosthesis System. The study will evaluate the safety of the device and surgery, as well as reliability of the system and the usefulness of any restored vision. Each subject will be followed for 6 years, with their health monitored throughout. Research sessions, visual function testing, and subject-reported outcomes will be used to evaluate the functioning of the system.

02

Conditions studied

  • Blindness, Acquired

Browse trials for

03

In context

Blindness

144 studies on the registry are indexed under Blindness; 33 are open to participants now.

This study's planned enrollment of 6 is below the median of 37 across 101 interventional studies indexed under Blindness.

Browse Blindness studies →

Lead sponsor

Second Sight Medical Products is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
22 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is bilaterally blind with bare or no light perception. This is defined as non-measurable binocular visual acuity or 5° or less visual field in each eye.
  2. Subject is bilaterally blind due to:

    1. Trauma to the eye, or
    2. Disease or damage of the retina (such as retinopathy, retinal vein occlusion, inherited retinal diseases or retinal detachment), or
    3. Disease or damage of the optic nerve or chiasm (such as glaucoma, methanol intoxication, neuropathies, pituitary pathology, and hereditary neuropathies)
  3. Subject's vision cannot be restored with any approved medication or intervention.
  4. Subject has a documented history of useful form vision.
  5. Subject is between the age of 22-74 .
  6. Subject resides within 2 hours (by ground transportation) of the site.
  7. Subject is (a) male or (b) a female of with a negative pregnancy test who is using a reliable method of or (c) a female who is at least two years or otherwise unable to bear children.
  8. Subject is able to complete regular office and telephone appointments per the protocol requirements.
  9. Subject is medically fit for neurosurgical intervention.

Exclusion criteria

Exclusion Criteria:

  1. Subject is at high risk for surgical complications such as active systemic infection, coagulation disorders (such as the use of anti-thrombotic therapies) or count below 100,000.
  2. Subject has history of bleeding or immune compromise.
  3. Subject is taking chronic anticoagulants or antiplatelet agent or subject has an abnormally elevated preoperative coagulation profile (either or PT/INR).
  4. Subject has had prior craniotomy or brain surgery that would interfere with placement or function of Orion device.
  5. Subject has evidence of active intracranial disease that would preclude elective neurosurgical intervention, such as unruptured intracranial aneurysm or brain tumor, or aberrant visual cortex anatomy, such as prior stroke or arteriovenous malformation.
  6. Subject has a significant abnormality on preoperative brain MRI.
  7. Subject has a prior history of seizures or epilepsy.
  8. Subject has Parkinson's disease.
  9. Subject has a prior history of serious head injury with loss of consciousness for more than 24 hours.
  10. Subject has a progressive central nervous system disease.
  11. Subject has a history of implant-related infection.
  12. Subject requires or is likely to require any of the following medical procedures while implanted with the Orion System: MR imaging, diathermy, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS). These medical procedures are for subjects implanted with an Orion System. Energy from these procedures can be sent through the implanted brain stimulation system and cause permanent brain damage which may cause severe injury, coma, or death.
  13. Subject is implanted with any neurostimulation or neuromodulation device in the head including, but not limited to cochlear implant, deep brain stimulator, or auditory brain implant.
  14. Subject has a or unstable medical condition including uncontrolled systemic hypertension with values above 170/100; cardiac or pulmonary disease; uncorrected coagulation abnormalities; diabetes; or any condition that would render the patient unable to safely cooperate with the study tests as judged by the screening physician.
  15. Subject has had an alcohol or illicit substance use disorder within the last 6 months, unstable remission of substance abuse, or chart evidence that co-morbid substance use disorder could account for lack of treatment response.
  16. Subject has uncontrolled chronic pain.
  17. Subject has significant neurocognitive impairment in memory domain (based on -BLIND \<18 or WAIS-IV \<80, described below).
  18. Subject had moderate or severe depression, as determined by a score of at least 17 on the HAM-D.
  19. Subject has had a suicide attempt in the last two years, presence of a suicide plan (an answer of "Yes" to Question C4 in Section C-Suicidality of MINI International Neuropsychiatric Interview), or a "yes" answer to any one of the ten suicidal ideation and behavior questions on the C-SSRS.
  20. Subject has a disease or condition that prevents understanding or communication of , study demands, or testing protocols, including:

    1. Cognitive decline including diagnosed forms of dementia and/or progressive neurologic disease
    2. Psychiatric disease including diagnosed forms of depression
    3. Does not speak a principal language associated with the region
    4. Deafness or selective frequency hearing loss that prevents adequate communication with the researchers.
  21. Subject has a balance disability or frequently participates in contact sports.
  22. Subject must administer diathermy as part of his/her livelihood.
  23. Subject is pregnant or is planning on becoming pregnant in the next year.
  24. Subject has unrealistic expectations of the benefits of the study.
  25. Subject is enrolled in another therapeutic drug or device trial
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Single Arm

    Implanted with the Orion Visual Cortical Prosthesis System

    Device: Orion Visual Cortical Prosthesis System

Interventions

  • DeviceOrion Visual Cortical Prosthesis System

    The Orion Visual Cortical Prosthesis System is intended to stimulate the medial surface of the occipital lobe in the visual cortex to induce visual perception in blind individuals.

06

What researchers measure

Primary outcomes

  1. Rate of Device- or Procedure-Related Adverse Events (Safety)

    Collection of adverse events

    Time frame: Through study completion, an average of 6 years

Secondary outcomes

  1. Ability to Create Visual Perception as Measured by Stimulation Thresholds

    Measurement of stimulation thresholds on each electrode or groups of electrodes

    Time frame: 1 month, 6 months, 12 months, 24 months, 60 months, 72 months

07

Study locations

2 sites
08

References and documents

Publications

  • Beauchamp MS, Oswalt D, Sun P, Foster BL, Magnotti JF, Niketeghad S, Pouratian N, Bosking WH, Yoshor D. Dynamic Stimulation of Visual Cortex Produces Form Vision in Sighted and Blind Humans. Cell. 2020 May 14;181(4):774-783.e5. doi: 10.1016/j.cell.2020.04.033. PubMed 32413298 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2017 (actual). Primary completion is estimated for Mar 2025, 88 months after the start.

Of 36 interventional studies with no phase under Blindness, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 19. This study's planned 88 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2017
First posted
Nov 17, 2017
StartActual
Nov 20, 2017
Primary completionEst.
Mar 31, 2025
CompletionEst.
Mar 31, 2025
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03344848
Lead sponsor
Second Sight Medical Products
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Nov 20, 2017
Primary completion
Mar 31, 2025 (estimated)
Completion
Mar 31, 2025 (estimated)
Last update
Jan 27, 2025

Study contacts

Uday Patel, PhD
study director · Second Sight Medical Products

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion